On 12 Nov 2026 Henry Schein closed at $86.14, +14.0% this year; market cap $9.69bn, P/E 23.0.
Health Care · Health Care Distributors · NASDAQ · United States
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
| Market cap | $9.69bn |
| P/E (trailing) | 23.0 |
| EPS (TTM) | $3.74 |
| Beta | 0.86 |
| Dividend | $0.00 |
| Dividend yield | 0.00% |
| Ex-dividend date | — |
| Latest report | 3 Nov 2026 |
| Next earnings | 2 Feb 2027 |
| YTD | +14.0% |
| 1Y | +18.3% |
| 3Y | +8.5% |
| 5Y | +1.7% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $13.18bn | $398.00m | $573.00m |
| 2024 | $12.67bn | $390.00m | $661.00m |
| 2023 | $12.34bn | $416.00m | $313.00m |
| 2022 | $12.65bn | $538.00m | $506.00m |
| 2021 | $12.40bn | $623.91m | $630.57m |
We publish no single base value for Henry Schein. Our valuation methods put it between $66.68 and $83.20 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.